Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THB335 in Adult Participants With Chronic Spontaneous Urticaria (CSU)
NCT07766499Phase 2Recruiting
- Sponsor
- Calixis
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of THB335 in chronic spontaneous urticaria (CSU), sponsored by Calixis. Started Sep 2026; status: recruiting.
02
Drugs
THB335
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07766499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07766499.